{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:07:42Z","timestamp":1777540062093,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Lamotrigine (LTG) is a widely used anti\u2010epileptic drug that is administered to avoid seizures and to maintain seizure\u2010free status. However, several factors reportedly cause individual differences of plasma LTG levels, and the therapeutic target range of LTG varies between individuals. Thus, to optimize effective doses of LTG, we developed a rapid and simple method for determining plasma LTG concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Lamotrigine and the internal standard papaverine were extracted from human plasma using solid\u2010phase extraction. After filtration, 5\u2010\u03bcL aliquots of final samples were injected into the liquid chromatography\u2010tandem mass spectrometry instrument and LTG and internal standard were separated using a Cadenza<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\u2010C18 column (100\u00a0\u00d7\u00a02\u00a0mm, 3\u00a0\u03bcm) with 0.1% formic acid in water\/acetonitrile (2\/1, v\/v).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The calibration curve was linear from 0.2 to 5.0\u00a0\u03bcg\/mL, and assessments of recovery, intra\u2010 and inter\u2010day precision and accuracy, matrix effects, freeze and thaw stability, and long\u2010term stability demonstrated good reproducibility. Retention times of LTG and internal standard were 1.6 and 2.0\u00a0minutes, respectively, and the total run time was 3.5\u00a0minutes for each sample.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a rapid and simple method for determining plasma LTG concentrations. The present novel system could be used to inform LTG dose adjustments for individual patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/npr2.12045","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T05:09:19Z","timestamp":1546492159000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Determination of lamotrigine in human plasma using liquid chromatography\u2010tandem mass spectrometry"],"prefix":"10.1002","volume":"39","author":[{"given":"Shogo","family":"Itabashi","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Bito","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maika","family":"Nishina","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-3447","authenticated-orcid":false,"given":"Midori","family":"Soda","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunori","family":"Doi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"},{"name":"Department of Pharmacy Wakayama Medical University Hospital Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Usui","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoyuki","family":"Kitaichi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics Department of Biomedical Pharmaceutics Gifu Pharmaceutical University Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"issue":"1","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":"Prospective study on concentration\u2010efficacy and concentration\u2010toxicity: correlations with lamotrigine serum levels","volume":"4","author":"Froscher W","year":"2002","journal-title":"Epileptic Disord"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2012.01351.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12584"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1925-9"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2008-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2014.12.007"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.35.487"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2015.01.001"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00818.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.06.023"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.02.005"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.02.020"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01007.x"},{"key":"e_1_2_12_15_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM).Bioanalytical method validation guidance for industry[Internet]. Rockville: U.S. Food and Drug Administration;2018[updated 2018 May]. Available fromhttps:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.Pdf"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201501067"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/48.5.375"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.11.040"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000123"},{"key":"e_1_2_12_20_1","unstructured":"GlaxoSmithKline K.K.Medicine interview form of Lamictal[Internet]. Tokyo: GlaxoSmithKline K.K. [updated September 2018]. Available from:\u00a0https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/ja_JP\/products-info\/lamictal\/lamictal-if.pdfo"},{"issue":"2","key":"e_1_2_12_21_1","first-page":"67","article-title":"Standardize guideline for TDM of antiepileptic drug 2017","volume":"304","author":"Tanigawara Y","year":"2017","journal-title":"Jpn J Ther Drug Monit"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2015.03.032"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1692"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.12.004"},{"key":"e_1_2_12_25_1","unstructured":"HeX KozakM.Simultaneous quantitation of 19 drugs in human plasma and serum by LC\u2010MS\/MS[Internet]. San Jose CA: Thermo Fisher Scientific [accessed 2018 April]. Available from:https:\/\/assets.thermofisher.com\/TFS-Assets\/CMD\/Application-Notes\/AN-571-LC-MS-Drugs-Human-Plasma-AN63671-EN.pdf"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.03.002"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2013.02.010"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.11.030"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5251-5"},{"key":"e_1_2_12_30_1","unstructured":"Waters Corporation.Topics in Solid\u2010Phase Extraction Part 1. Ion suppression in LC\/MS analysis: a review strategies for its elimination by well\u2010designed multidimensional solid\u2010phase extraction (SPE) protocols and methods for its quantitative assessment[Internet]. Milford: Waters Corporation [accessed 2018 April]. Available from:https:\/\/www.waters.com\/webassets\/cms\/library\/docs\/720001273en.pdf."},{"issue":"1","key":"e_1_2_12_31_1","first-page":"12","article-title":"Strategies & considerations for bio analytical method development and validation using LCMS\/MS: a review","volume":"6","author":"Malodia K","year":"2011","journal-title":"Pharm Res"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.09.041"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnpr2.12045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T19:39:49Z","timestamp":1720899589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/npr2.12045"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12045","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"2018-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}